The company’s research reveals that AP-SA02 maintains a reproducible profile of genetic variants through controlled manufacturing processes. During in vitro testing on isolates from the Phase 1b/2a diSArm study, select variants within the cocktail became enriched when exposed to particular bacterial strains. This suggests these specific variants are optimized to infect and replicate on distinct clinical isolates. Experiments using phage stocks lacking these variants showed diminished activity, confirming the functional role of the diversity in the drug's performance.
In section Releases
Armata Links Genetic Diversity to Phage Therapy Efficacy
Armata Pharmaceuticals is presenting new data at the 2026 International Symposium on Staphylococci and Staphylococcal Infections in Banff, showing that intentional genetic diversity within its AP-SA02 bacteriophage cocktail enhances the product's ability to eliminate specific Staphylococcus aureus clinical isolates.
Dr. Deborah Birx, CEO of Armata, stated that this controlled genomic diversity allows the cocktail to adapt to a wide range of genetically and geographically diverse MRSA and MSSA isolates. These findings reinforce the company's progress following the Phase 2a diSArm study, where all evaluable participants achieved a complete clinical response. Armata is now preparing to transition AP-SA02 into a Phase 3 superiority study for complicated S. aureus bacteremia, which is expected to begin in the second half of 2026.
Comments (0)
No comments yet. Be the first!